AzTrials
AzTrials

STOMACH NEOPLASMNCT07828899

Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer

A study testing Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy in people with STOMACH NEOPLASM and Robotic Surgical Procedures, run by First Affiliated Hospital of Wenzhou Medical University at 5 sites in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This multicenter randomized non-inferiority trial evaluates single-port versus multi-port robotic-assisted radical distal gastrectomy in patients with gastric cancer. A prespecified prospective substudy will assess early postoperative pain, abdominal wall trauma, and early recovery between the two surgical approaches. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
STOMACH NEOPLASM, Robotic Surgical Procedures
What is being tested?
Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
212 participants
Where
5 sitesChina
Study dates
Oct 2026to Nov 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-85 years, irrespective of sex.
  • Histologically confirmed primary gastric adenocarcinoma based on endoscopic biopsy.
  • The primary tumor is located in the middle or distal third of the stomach, or at another site considered amenable to radical distal gastrectomy. Preoperative evaluation indicates that robot-assisted radical distal gastrectomy is technically feasible and that an R0 resection is anticipated. Patients who have received standard neoadjuvant therapy may also be eligible if reassessment confirms fulfillment of the above surgical criteria.
  • Clinical stage cT1-3N0-1M0 according to the 8th edition of the AJCC TNM staging system for gastric cancer, as assessed by gastroscopy and contrast-enhanced computed tomography of the chest, abdomen, and pelvis, with endoscopic ultrasonography, abdominal magnetic resonance imaging, or diagnostic laparoscopy performed when clinically indicated. Preoperative assessment should indicate that R0 resection can be achieved by distal gastrectomy, with no evidence of adjacent organ invasion or distant metastasis.
  • No history of other malignancies within the preceding 5 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies with a similarly negligible risk of recurrence.
  • American Society of Anesthesiologists (ASA) physical status class I-III.
Show all 9Show fewer
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.
  • Adequate major organ function, with preoperative assessment confirming fitness for general anesthesia and robot-assisted radical distal gastrectomy.
  • Subjects voluntarily participate in the study, fully understand the trial protocol and provide written informed consent.

Who cannot join

  • Body mass index (BMI) >35 kg/m².
  • Previous gastrectomy, or a history of major upper abdominal surgery considered likely to substantially compromise the feasibility or safety of robot-assisted distal gastrectomy, such as complex hepatobiliary-pancreatic surgery or surgery involving the esophagogastric junction. Previous uncomplicated laparoscopic cholecystectomy, appendectomy, or similar procedures are not, in principle, considered exclusionary.
  • Tumor-related acute obstruction, active major hemorrhage, or perforation requiring emergency surgery.
  • Preoperative confirmation of synchronous multiple gastric cancers or remnant gastric cancer, or the presence or history within the preceding 5 years of another active malignancy that may interfere with study treatment or assessment of study endpoints.
  • Preoperative assessment indicating that radical distal gastrectomy is oncologically or technically inappropriate, including anticipated requirement for total gastrectomy, proximal gastrectomy, combined esophagectomy, or any other procedure other than distal gastrectomy.
  • Preoperative evaluation or diagnostic laparoscopy demonstrating definite invasion of adjacent organs requiring en bloc multivisceral resection; distant metastasis, including peritoneal, hepatic, pulmonary, osseous, or distant lymph-node metastasis; or positive peritoneal lavage cytology.
Show all 12Show fewer
  • Standard preoperative evaluation indicating that the patient is not currently an appropriate candidate for upfront radical distal gastrectomy and requires initiation or continuation of neoadjuvant therapy or other antineoplastic treatment.
  • Concomitant disease requiring an additional surgical procedure at the time of radical gastrectomy that may substantially affect operative duration, perioperative safety, postoperative recovery, or assessment of the primary endpoint.
  • Pregnancy or lactation, or planned pregnancy during the study period.
  • Severe cardiac, pulmonary, hepatic, or renal dysfunction; severe coagulation abnormalities; uncontrolled infection; or any other medical condition considered to preclude safe administration of general anesthesia or surgical treatment.
  • Inability to provide valid informed consent because of cognitive impairment, psychiatric or mental status abnormalities, or other reasons, or inability to comply with protocol-specified treatment and follow-up procedures.
  • Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the study.

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

5 sites in 1 country

China5 sites
  • Beijing Tsinghua Changgung Hospital

    Beijing

    Guoxin Li

  • PLA Army Characteristic Medical Center

    Chongqing

    Fan Li

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong

    Leping Li

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Qun Zhao

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000

Other trials in China

About this study

Official title: Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer: a Multicenter, Prospective, Open-Label, Randomized Controlled Trial

This multicenter randomized non-inferiority trial evaluates single-port versus multi-port robotic-assisted radical distal gastrectomy in patients with gastric cancer. A prespecified prospective substudy will assess early postoperative pain, abdominal wall trauma, and early recovery between the two surgical approaches.

Being tested
Single-Port Robot-Assisted Radical Distal Gastrectomy, Multi-Port Robot-Assisted Radical Distal Gastrectomy
Medical subject headings
Stomach Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Single-Port Robot-Assisted Radical Distal GastrectomyProcedure or surgery

    Participants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a single-port surgical approach. The surgical procedure will be performed according to the predefined study protocol.

  • Multi-Port Robot-Assisted Radical Distal GastrectomyProcedure or surgery

    Participants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a multi-port surgical approach. The surgical procedure will be performed according to the predefined study protocol.

Study groups in NCT07828899
Study groupRoleWhat they receive
Single-Port Robotic Gastrectomy GroupExperimentalParticipants randomized to this group will undergo single-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol
Receives: Procedure: Single-Port Robot-Assisted Radical Distal Gastrectomy
Multi-Port Robotic Gastrectomy GroupActive comparatorParticipants randomized to this group will undergo conventional multi-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol
Receives: Procedure: Multi-Port Robot-Assisted Radical Distal Gastrectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Technical Success of the Randomly Assigned Robotic Surgical Approach

    Technical success is defined as completion of the protocol-specified gastrectomy, lymph node dissection, and gastrointestinal reconstruction using the robotic surgical approach assigned at randomization. In the single-port group, technical success requires completion using the single-port robotic system without conversion to multi-port robotic surgery, conventional laparoscopic surgery, or open surgery, and without any unplanned additional port beyond those permitted by the protocol. In the multi-port group, technical success requires completion using the multi-port robotic system without conversion to conventional laparoscopic surgery or open surgery. Failure to complete the assigned robotic procedure because of participant-related, operative, or device-related reasons will be classified as technical failure. The prespecified noninferiority margin is -10 percentage points.

    Measured: At the end of surgery

Secondary outcomes (28)
  1. Total Operative Time

    Total duration of the surgical procedure, recorded in minutes according to the protocol-defined timing criteria.

    Measured: Intraoperative

  2. Robotic Docking Time

    Duration required for robotic docking, recorded in minutes according to the protocol-defined timing criteria.

    Measured: Intraoperative

  3. Robotic Console Time

    Duration of robotic console operation, recorded in minutes according to the protocol-defined timing criteria.

    Measured: Intraoperative

  4. Intraoperative Blood Loss

    Estimated volume of blood loss during surgery, recorded in milliliters.

    Measured: Intraoperative

  5. Percentage of Participants With Intraoperative Complications

    Intraoperative complications will be recorded and graded according to the Satava classification system.

    Measured: Intraoperative

  6. Percentage of Participants With R0 Resection

    R0 resection is defined as complete tumor resection with no microscopic residual tumor at the resection margins, as determined by postoperative pathological examination.

    Measured: At completion of postoperative pathological assessment, within 30 days after surgery

  7. Number of Lymph Nodes Retrieved

    Total number of lymph nodes retrieved and identified during postoperative pathological examination.

    Measured: At completion of postoperative pathological assessment, within 30 days after surgery

  8. Number of Metastatic Lymph Nodes

    Total number of pathologically confirmed metastatic lymph nodes identified during postoperative pathological examination.

    Measured: At completion of postoperative pathological assessment, within 30 days after surgery

  9. Overall postoperative complications

    Any postoperative complication occurring from the end of surgery through postoperative Day 30 will be recorded according to the predefined study protocol and graded using the Clavien-Dindo classification.

    Measured: From the end of surgery through 30 days after surgery

  10. Percentage of Participants With Clavien-Dindo Grade III or Higher Postoperative Complications

    Severe postoperative complications are defined as postoperative complications classified as Clavien-Dindo Grade III or higher.

    Measured: From the end of surgery through 30 days after surgery

  11. Specific surgery-related complications

    Prespecified surgery-related complications include anastomotic leakage, anastomotic bleeding or stenosis, duodenal stump leakage, pancreatic fistula or postoperative pancreatitis, intra-abdominal bleeding, intra-abdominal infection or abscess, bile leakage, chylous or lymphatic leakage, delayed gastric emptying, postoperative ileus or bowel obstruction, internal hernia, bowel perforation or ischemic necrosis, and wound complications requiring clinical intervention.

    Measured: From the end of surgery through 30 days after surgery

  12. Percentage of Participants With Unplanned Reoperation Within 30 Days After Surgery

    Percentage of participants requiring an unplanned surgical reoperation for any postoperative reason within 30 days after the index surgery.

    Measured: Within 30 days after surgery

  13. Percentage of Participants With Unplanned Readmission Within 30 Days After Surgery

    Percentage of participants requiring an unplanned hospital readmission within 30 days after the index surgery.

    Measured: Within 30 days after surgery

  14. Percentage of Participants Who Die Within 30 Days After Surgery

    All-cause mortality occurring within 30 days after the index surgery.

    Measured: Within 30 days after surgery

  15. Pain and Early Recovery Substudy: Estimated Marginal Mean Resting VAS Pain Score Across Postoperative Days 1-3

    This is the prespecified primary outcome of the embedded postoperative pain and early recovery substudy, which is planned to include 140 participants from the parent randomized trial. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Days 1, 2, and 3 according to a standardized assessment procedure. For the primary analysis, a linear mixed-effects model for repeated measures will be applied, adjusting for pre-specified confounding factors including study site. It will estimate the overall mean resting VAS score across postoperative Days 1-3 for each group, together with the between-group difference and its 95% confidence interval. Higher VAS scores indicate greater pain intensity. The prespecified superiority hypothesis evaluates whether the overall resting VAS pain level across postoperative Days 1-3 is lower in the single-port group than in the multi-port group.

    Measured: Postoperative Days 1 through 3

  16. Pain and Early Recovery Substudy: Resting VAS Pain Score at 6 Hours After Surgery

    This is a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) at 6 hours after surgery according to the standardized assessment procedure. Higher VAS scores indicate greater pain intensity.

    Measured: 6 hours after surgery

  17. Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 1

    This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 1 according to the standardized assessment procedure. VAS scores on postoperative Day 1 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 1 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.

    Measured: Postoperative Day 1

  18. Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 2

    This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 2 according to the standardized assessment procedure. VAS scores on postoperative Day 2 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 2 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.

    Measured: Postoperative Day 2

  19. Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 3

    This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 3 according to the standardized assessment procedure. VAS scores on postoperative Day 3 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 3 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.

    Measured: Postoperative Day 3

  20. Pain and Early Recovery Substudy: Percentage of Participants Requiring Rescue Analgesia

    This is a prespecified secondary or supportive outcome of the embedded postoperative pain and early recovery substudy. Rescue analgesia is defined as additional analgesic treatment administered because of inadequate pain control beyond the protocol-specified routine postoperative analgesic regimen. The proportion of participants requiring at least one rescue analgesic intervention during the prespecified postoperative observation period will be recorded and compared between the single-port and multi-port groups. This outcome does not have a separate confirmatory superiority hypothesis.

    Measured: From the end of surgery through postoperative Day 3

  21. Pain and Early Recovery Substudy: Cumulative Postoperative Opioid Consumption in Morphine Milligram Equivalents

    This is a prespecified secondary or supportive outcome of the embedded postoperative pain and early recovery substudy. All postoperative opioid analgesics administered during the prespecified observation period will be recorded. Individual opioid doses will be converted to morphine milligram equivalents (MME) using a prespecified standardized conversion method, and cumulative MME will be calculated for each participant to allow quantitative comparison of postoperative opioid requirements between the single-port and multi-port groups. This outcome does not have a separate confirmatory superiority hypothesis.

    Measured: From the end of surgery through postoperative Day 3

  22. Total Abdominal Wall Incision Length

    Total abdominal wall incision length will be calculated as the sum of the lengths of all abdominal surgical incisions and recorded in centimeters according to the standardized study assessment procedure. This outcome will be assessed in randomized participants to compare abdominal wall trauma between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.

    Measured: At the end of surgery

  23. Maximum Length of a Single Abdominal Wall Incision

    The length of the longest individual abdominal wall surgical incision will be measured in centimeters according to the standardized study assessment procedure. This outcome will be assessed in randomized participants to compare the extent of abdominal wall trauma between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.

    Measured: At the end of surgery

  24. Time to First Postoperative Flatus

    Time to first postoperative flatus is defined as the time from the end of surgery to the first passage of flatus and will be recorded in hours. This outcome will be assessed in randomized participants to compare early postoperative gastrointestinal recovery between the single-port and multi-port robotic surgical groups.

    Measured: Up to 30 days after surgery

  25. Time to First Postoperative Defecation

    Time to first postoperative defecation is defined as the time from the end of surgery to the first postoperative bowel movement and will be recorded in hours. This outcome will be assessed in randomized participants to compare early postoperative gastrointestinal recovery between the single-port and multi-port robotic surgical groups.

    Measured: Up to 30 days after surgery

  26. Time to First Postoperative Ambulation

    Time to first postoperative walking lasting more than 5 minutes is defined as the time from the end of surgery to the first postoperative walking episode lasting more than 5 minutes and will be recorded in hours. Brief standing or walking episodes lasting 5 minutes or less will not be considered as meeting this outcome. This outcome will be assessed in randomized participants to compare early postoperative functional recovery between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.

    Measured: Up to 30 days after surgery

  27. Time to First Postoperative Oral Intake

    Time to first postoperative oral intake is defined as the time from the end of surgery to the first postoperative oral intake of liquid, soft food, or regular food and will be recorded in days. This outcome will be assessed in randomized participants to compare early postoperative recovery between the single-port and multi-port robotic surgical groups.

    Measured: Up to 30 days after surgery

  28. Time to Meeting Discharge Criteria

    Time to meeting discharge criteria is defined as the time from the end of surgery until the participant meets all prespecified discharge criteria. These criteria include stable vital signs without fever; recovery of gastrointestinal function with adequate oral intake and no requirement for intravenous nutritional support; ability to ambulate independently without significant discomfort; and satisfactory wound and drainage status with laboratory findings considered clinically acceptable according to the study protocol. This outcome will be assessed in randomized participants to compare early postoperative recovery between the single-port and multi-port robotic surgical groups.

    Measured: Up to 30 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionOct 2027 (estimated)
  4. Study completionNov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
212 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07828899
Sponsor's protocol ID
KY2026-423
Status last verified
Sep 2026
First submitted
4 Sep 2026
Last updated
18 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy in people with STOMACH NEOPLASM and Robotic Surgical Procedures, run by First Affiliated Hospital of Wenzhou Medical University at 5 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xian Shen, PhD (+86 139 6888 8872, shenxian1120@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Technical Success of the Randomly Assigned Robotic Surgical Approach (time frame: At the end of surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in